Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "EDS"

1510 News Found

Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases
News | June 10, 2025

Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases

Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,


Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025
Policy | June 09, 2025

Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025

Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme


Thyrocare opens diagnostic lab in Srinagar
News | June 06, 2025

Thyrocare opens diagnostic lab in Srinagar

33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley


Amyris expands precision fermentation line in Brazil
Biotech | June 04, 2025

Amyris expands precision fermentation line in Brazil

Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M


Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr
News | May 30, 2025

Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr

The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago


Sudeep Pharma acquires Nutrition Supplies Services
News | May 30, 2025

Sudeep Pharma acquires Nutrition Supplies Services

This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio


Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer
Drug Approval | May 29, 2025

Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer

This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition